RG 7304

Drug Profile

RG 7304

Alternative Names: CH-5126766; CKI-27; R-7304; RG-7304; RO-5126766

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche; Royal Marsden NHS Foundation Trust
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Feb 2013 RG 7304 is still in phase I development for Solid tumours
  • 30 Oct 2009 Phase-I development is ongoing
  • 12 Jan 2009 Phase-I clinical trials in Solid tumours (Late-stage disease) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top